Daptomycin nonsusceptible enterococci: An emerging challenge for clinicians

Clinical Infectious Diseases

Volumn 52, Issue 2, 2011, Pages 228-234

  Kelesidis, Theodoros ^a   Humphries, Romney ^a   Uslan, Daniel Z ^a   Pegues, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM; DAPTOMYCIN; GENTAMICIN; LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; AWARENESS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CLINICAL LABORATORY; DRUG MEGADOSE; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79951833552     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq113     Document Type: Article

References (78)

1. Eliopoulos GM. Microbiology of drugs for treating multiply drugresistant gram-positive bacteria. J Infect 2009;59: S17-24.
2. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. CLSI, 2010; M100-S20. Available at http://www.clsi.org/source/orders/free/m100-s20-u. pdf.
3. Package insert. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, 2007.
4. Rathe M, Kristensen L, Ellermann-Eriksen S, Thomsen MK, Schumacher H. Vancomycin-resistant Enterococcus spp: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS 2010;118:66-73.
5. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009;65:158-62.
6. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33:543-48.
7. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycinresistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the van A gene cluster. Clin Infect Dis 2007;45:1343-6. (Pubitemid 351411911)
8. Hidron AI, Schuetz AN, Nolte FS, Gould CV, Osborn MK. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 2008;61:1394-6. (Pubitemid 351753616)
9. Kanafani ZA, Federspiel JJ, Fowler VG Jr. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis 2007;39:75-7. (Pubitemid 46296475)
10. Lee dK, Kim Y, Park KS, Yang JW, Kim K, Ha NJ. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005). J Biochem Mol Biol 2007;40:881-7. (Pubitemid 350242272)
11. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-17. (Pubitemid 350016703)
12. Fraher MH, Corcoran GD, Creagh S, Feeney E. Daptomycin-resistant Enterococcus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 2007;65:376-8. (Pubitemid 46477977)
13. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 2007;30:143-9. (Pubitemid 46977187)
14. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007;57:459-65. (Pubitemid 46498660)
15. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006;12:844-52. (Pubitemid 44151284)
16. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 2006;12:179-81. (Pubitemid 44696445)
17. Lesho EP, Wortmann GW, Craft D, Moran KA. De novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 2006;44:673. (Pubitemid 43222282)
18. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006;28:385-8. (Pubitemid 44636192)
19. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timedkill curves. J Chemother 2005;17:614-21. (Pubitemid 43097748)
20. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-6. (Pubitemid 41133543)
21. Sader HS, Fritsche TR, Streit JM, Jones RN. Daptomycin in vitro activity tested against gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother 2005;17:477-83. (Pubitemid 41695594)
22. Lewis JS, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49:1664-5. (Pubitemid 40463418)
23. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005;41:565-6. (Pubitemid 41099656)
24. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycinresistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 2005;80:1215-6. (Pubitemid 41233359)
25. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother 2004;53:669-74. (Pubitemid 38499788)
26. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. Daptomycin in vitro susceptibility in European gram-positive clinical isolates. Int J Antimicrob Agents 2004;24:59-66. (Pubitemid 38844564)
27. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003;47:3760-3. (Pubitemid 37484984)
28. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000. (Pubitemid 38457208)
29. Debbia E, Pesce A, Schito GC. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother 1988;32:279-81. (Pubitemid 18061394)
30. Debono M, Abbott BJ, Molloy RM, et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot (Tokyo) 1988;41:1093-105.
31. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991;35:92-8.
32. Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 1993;39:302-9.
33. Wang JT, Chen YC, Chang SC, et al. Control of vancomycin-resistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital. J Hosp Infect 2004;58:97-103.
34. Masterton RG. Surveillance studies: how can they help the management of infection? J Antimicrob Chemother 2000;46:53-8.
35. WHO. Antimicrobial resistance information bank. http://www.who. int/emc/amr.html. Last accessed 1 October 2010.
36. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 2006;311:374-7. (Pubitemid 43132661)
37. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003;47:1689-93. (Pubitemid 36548555)
38. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-802. (Pubitemid 32466351)
39. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:2137-45. (Pubitemid 43807536)
40. Montero CI, Stock F, Murray PR. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 2008;52:1167-70. (Pubitemid 351358408)
41. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45:601-8. (Pubitemid 47328642)
42. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42:1652-3.
43. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility vancomycin and resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-82. (Pubitemid 43327815)
44. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr., Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-5.
45. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004;50:201-4. (Pubitemid 39487294)
46. Jevitt LA, Thorne GM, Traczewski MM, et al. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycinsusceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 2006;44:3098-104. (Pubitemid 44413737)
47. Johnson AP, Mushtaq S, Warner M, Livermore DM. Calciumsupplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. J Antimicrob Chemother 2004;53:860-2. (Pubitemid 38660292)
48. Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 2000;38:51-8.
49. Fuchs PC, Barry AL, Brown SD. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother 2001;48:557-61. (Pubitemid 33040700)
50. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. Wayne, PA: CLSI, 2006; M100-S16.
51. Aldridge KE, Dizney A, Thomson K, Procop G. A multicentre correlation study of VITEK 2 with reference methods for telithromycin, mupirocin, and daptomycin against Staphylococcus spp. [abstract 1134-02-406 XXI ISTH Congress. Oxford, UK 2007.
52. Kelley TM, Knapp CC, Killian S, et al. Multi-site evaluation of daptomycin on the Sensititre dried susceptibility plate compared to NCCLS microdilution method. Intersci Conf Antimicrob Agents Chemother Chicago 14-17 September 2003. 43: [abstract D-225] 2003.
53. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009;9:617-24.
54. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539-46. (Pubitemid 37338519)
55. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454-9. (Pubitemid 32105280)
56. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60:334-40. (Pubitemid 47243883)
57. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
58. Cunha BA, Mickail N, Eisenstein L. E faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007;36:456-61. (Pubitemid 350086682)
59. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006;18:27-32.
60. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:2871-5. (Pubitemid 38989149)
61. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007;51:1504-7. (Pubitemid 46586838)
62. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005;49:2735-45. (Pubitemid 40917586)
63. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53:530-2. (Pubitemid 38380256)
64. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005;49:5166-8. (Pubitemid 41778943)
65. Rand KH, Houck HJ, Silverman JA. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 2007;59:1017-20. (Pubitemid 47073378)
66. Sakoulas G, Moise PA, Nizet V. Ampicillin. enhances the activity of daptomycin by alteration of surface charge in vancomycin-resistant Enterococcus faecium. Presented at: Conference on Antimicrobial agents and chemotherapy, 12-15 September 2009. San Francisco, CA: 2009.
67. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26:43-9.
68. Huang YT, Liao CH, Teng LJ, Hsueh PR. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of gram-positive bacteria in Taiwan. Clin Microbiol Infect 2008;14:124-9.
69. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int J Antimicrob Agents 2010;35:451-6.
70. Bush LM, Boscia JA, Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother 1988;32:877-81.
71. Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992;36:2611-6.
72. LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009;53:3880-6.
73. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006;38:133-6. (Pubitemid 43203242)
74. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1714-8. (Pubitemid 36548559)
75. John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009;53:2719-24.
76. Jenkins I. Linezolid-vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-4. (Pubitemid 350020012)
77. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009;43:2108-12.
78. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010;29:379-81.